- Home
- AVAV vs BPMC Comparison
AVAV vs BPMC Comparison
Compare AVAV & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVAV
- BPMC
- Stock Information
- Founded
- AVAV 1971
- BPMC 2008
- Country
- AVAV United States
- BPMC United States
- Employees
- AVAV N/A
- BPMC N/A
- Industry
- AVAV Aerospace
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- AVAV Industrials
- BPMC Health Care
- Exchange
- AVAV Nasdaq
- BPMC Nasdaq
- Market Cap
- AVAV 7.4B
- BPMC 8.3B
- IPO Year
- AVAV 2007
- BPMC 2015
- Fundamental
- Price
- AVAV $265.00
- BPMC $129.36
- Analyst Decision
- AVAV Strong Buy
- BPMC Buy
- Analyst Count
- AVAV 9
- BPMC 20
- Target Price
- AVAV $265.22
- BPMC $127.82
- AVG Volume (30 Days)
- AVAV 2.4M
- BPMC 3.4M
- Earning Date
- AVAV 09-03-2025
- BPMC 07-31-2025
- Dividend Yield
- AVAV N/A
- BPMC N/A
- EPS Growth
- AVAV N/A
- BPMC N/A
- EPS
- AVAV 1.55
- BPMC N/A
- Revenue
- AVAV $820,627,000.00
- BPMC $562,121,000.00
- Revenue This Year
- AVAV $149.20
- BPMC $44.46
- Revenue Next Year
- AVAV $15.45
- BPMC $32.78
- P/E Ratio
- AVAV $171.15
- BPMC N/A
- Revenue Growth
- AVAV 14.50
- BPMC 99.19
- 52 Week Low
- AVAV $102.25
- BPMC $73.04
- 52 Week High
- AVAV $295.90
- BPMC $129.49
- Technical
- Relative Strength Index (RSI)
- AVAV 69.13
- BPMC 76.87
- Support Level
- AVAV $228.89
- BPMC $129.00
- Resistance Level
- AVAV $295.90
- BPMC $129.49
- Average True Range (ATR)
- AVAV 15.01
- BPMC 0.25
- MACD
- AVAV -0.04
- BPMC -0.92
- Stochastic Oscillator
- AVAV 71.39
- BPMC 90.91
About AVAV AeroVironment Inc.
AeroVironment Inc operates under a single business segment in which it supplies unmanned aircraft systems, tactical missile systems, high-altitude pseudo-satellites, and other related services to government agencies within the United States Department of Defense as well as the United States allied international governments. The systems can help with security, surveillance, or sensing, and provide eyes in the sky without needing an actual person, or driver in the sky.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.